Hadassah

Melanoma

Melanoma  is the most dangerous form of skin cancer. It occurs when there is damage to the DNA that controls cell growth and it is most often caused by ultraviolet radiation from sunshine or tanning salons. The damage triggers mutations which cause the skin cells to multiply rapidly and form malignant tumors. If diagnosed and treated early, melanoma is almost always curable, but if not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal.

Meet Melanoma Survivors Hannah Rapaport & Stewart Greenberg

Hannah Rapaport was told she had a 5% chance of survival. At best. That was before she found HMO. Since then, she's celebrated more than a dozen years of simchas with her family, thanks to Dr. Michal Lotem of the Hadassah Melanoma and Cancer Immunotherapy Center. HMO doctor/researchers work year-round to create cutting-edge treatments that save lives, like Hannah's. Watch her powerful story.

Stewart Greenberg lawyer, husband, grandfather — was diagnosed with stage four melanoma in 2012. Now cancer-free, Stewart wants the world to know that the Hadassah Medical Organization is changing the way we fight cancer. Read Stewart's story here ›

 

RESEARCH

The Hadassah Melanoma and Cancer Immunotherapy Center (HMCIC), headed by Prof. Michal Lotem, offers several treatments—unique in the world—aimed at strengthening the patient’s immune response to a tumor. Treatments are designed for at stage III and IV patients who have undergone surgery for metastases. Over 200 patients with metastatic melanoma (melanoma that has spread) have been successfully treated over the past 16 years in the Center.

The MHCIC offers two vaccine immunotherapies:

  • Autologous Vaccine, prepared with cells from the patient’s own tumor
  • Allogeneic Vaccine, engineered to stimulate a more powerful immune response and prepared from a tumor cell line generated at the Center

The vaccination protocol can be used for other cancers besides melanoma, including cancer of the colon, prostate, ovary, lung, and kidney.



COLLABORATIONS:

Melanoma Research Alliance, Washington, DC National Cancer Institute, Bethesda, MD

NEXT STEPS:

The HMCIC often takes part in clinical trials sponsored by pharmaceutical companies developing new drugs for the treatment of metastatic melanoma. The HMCIC also has several active research programs aimed at enhancing the efficacy of melanoma immunotherapy. One of these includes a adoptive cell therapy, where lymphocytes—a type of white blood cells that can kill cancer cells—are extracted from a melanoma tumor, multiplied in the laboratory, and then returned to the patient.

GENDER EQUITY:

Worldwide, medical research disproportionately focuses on men – leading to misdiagnosis and compromised care for women. Join Hadassah and advocate for gender equity in medical research (GEM). Learn more at hadassah.org/GEM

THE POWER IS IN YOUR HANDS

DONATE TODAY. SAVE LIVES TOMORROW.

News & Stories

alt_text

Wednesday, Jul 12 2017

The Woman Behind the Trailblazing Treatment

Hadassah’s Prof. Michal Lotem, a trailblazer in melanoma research and healing, is treating her...

READ MORE ›
alt_text

Thursday, Sep 15 2016

From Stage-Four Melanoma to Cancer-Free, Thanks to HMO

"Doctors in Florida who pronounced me ‘soon-dead’ can't believe that I'm healthy today,” said...

READ MORE ›
alt_text

Tuesday, Apr 28 2015

Hadassah Melanoma Specialist Awarded Grant for Advanced Research

The Melanoma Research Alliance (MRA) awarded Dr. Michal Lotem and his team $337,500 over three...

READ MORE ›
alt_text

Tuesday, Apr 28 2015

Hadassah Melanoma Specialist Awarded Grant for Advanced Research

NEW YORK, NY–April 27 — Dr. Lotem, head of Hadassah Medical Organization's Center for Melanoma...

READ MORE ›

See More News

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More